28. April 2022 | Corporate News

Marinomed’s Australian Carragelose distribution network strengthened

Press release

Marinomed Biotech AG (VSE:MARI), an Austrian science-based biotech company with globally marketed therapeutics, announced today that Aspen Pharmacare Australia Pty Ltd, one of Australia’s largest pharmaceutical companies, has become their distribution partner for Carragelose-based nasal sprays. Aspen has recently acquired ENT Technologies Pty Ltd (ENTT), which has been marketing Carragelose as Flo™ Travel, a protective nasal spray with virus-trapping capability, in Australia. Aspen takes over ENTT’s range of Flo-branded nasal and sinus products and continues marketing the Flo™ Travel spray. Aspen’s highly rated Health Care Professional field force and extensive marketing capabilities provide resources to drive growth further.

The acquisition of ENTT presents an attractive opportunity for Aspen to become a category leader with a portfolio of highly regarded products that fit perfectly into Aspen’s existing consumer portfolio in the Australian markets. “We are looking forward to continuing the successful partnership we established with ENTT in Australia with Aspen. Backed by their know-how and resources, we hope to further increase the reach of Carragelose-based nasal sprays so more people can profit from their virus-blocking action, especially as the cold and flu season is just starting in the Southern hemisphere,” said Dr. Cornelia Kutzer, CBO of Marinomed.

The full press release is available as download here:

Marinomed’s Australian Carragelose distribution network strengthened
(85 KB)